bosentan anhydrous has been researched along with Atherosclerosis in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, G; Xu, X; Zhao, Z | 1 |
| Acin, F; Bleda, S; De Haro, J; Gonzalez-Hidalgo, C; Michel, I | 1 |
| Bouras, G; Cleman, MW; Deftereos, S; Giannopoulos, G; Kaoukis, A; Panagopoulou, V; Papoutsidakis, N; Raisakis, K; Stefanadis, C | 1 |
| Courtman, DW; Rampersad, SN; Stewart, DJ; Suen, RS | 1 |
| Davenport, AP; Maguire, JJ | 1 |
| Delgado, DH; Jackman, J; Ramzy, D; Rao, V; Ross, HJ; Sheshgiri, R; Tumiati, LC; Xu, N | 1 |
2 review(s) available for bosentan anhydrous and Atherosclerosis
| Article | Year |
|---|---|
The role of endothelin system in cardiovascular disease and the potential therapeutic perspectives of its inhibition.
Topics: Animals; Atherosclerosis; Atrial Fibrillation; Bosentan; Cardiovascular Diseases; Coronary Artery Disease; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Humans; Hypertension, Pulmonary; Phenylpropionates; Predictive Value of Tests; Pyridazines; Receptors, Endothelin; Sulfonamides | 2013 |
Endothelin.
Topics: Amino Acid Sequence; Animals; Antihypertensive Agents; Aspartic Acid Endopeptidases; Atherosclerosis; Binding Sites; Bosentan; Endothelin-Converting Enzymes; Endothelins; Endothelium, Vascular; Humans; Hypertension; Hypertension, Pulmonary; Metalloendopeptidases; Molecular Sequence Data; Muscle, Smooth, Vascular; Receptors, Endothelin; Signal Transduction; Sulfonamides; Vasoconstrictor Agents; Viper Venoms | 2006 |
1 trial(s) available for bosentan anhydrous and Atherosclerosis
| Article | Year |
|---|---|
Long-Term Effects of Bosentan on Cardiovascular Events in Hispanic Patients with Intermittent Claudication: Four-Year Follow-up of the CLAU Trial : The CLAU Randomized Trial Long-Term Outcome.
Topics: Antihypertensive Agents; Atherosclerosis; Bosentan; Follow-Up Studies; Hispanic or Latino; Humans; Intermittent Claudication; Male; Middle Aged; Peripheral Arterial Disease; Treatment Outcome | 2019 |
3 other study(ies) available for bosentan anhydrous and Atherosclerosis
| Article | Year |
|---|---|
The Protective Effect of Bosentan against Atherosclerosis in Apolipoprotein E-Deficient Mice Is Mediated by miRNA-21.
Topics: Animals; Aorta, Thoracic; Apolipoproteins E; Apoptosis Regulatory Proteins; Atherosclerosis; bcl-2-Associated X Protein; Body Weight; Bosentan; Caspase 3; Diet, High-Fat; Lipids; Mice; Mice, Inbred C57BL; MicroRNAs; Protective Agents; RNA-Binding Proteins; RNA, Messenger | 2019 |
Differential roles of endothelin-1 in angiotensin II-induced atherosclerosis and aortic aneurysms in apolipoprotein E-null mice.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta; Aortic Aneurysm; Apolipoproteins E; Atherosclerosis; Biomechanical Phenomena; Bosentan; Cardiovascular Agents; Cell Adhesion; Collagen; Down-Regulation; Endothelin-1; Integrin beta1; Interferon-gamma; Mice; Mice, Knockout; Stress, Physiological; Sulfonamides; Vasoconstrictor Agents | 2011 |
Endothelin-1 accentuates the proatherosclerotic effects associated with C-reactive protein.
Topics: Alkaloids; Atherosclerosis; Benzophenanthridines; Bosentan; C-Reactive Protein; Cells, Cultured; Cytokines; Endothelin-1; Endothelium, Vascular; Homeostasis; Humans; Naphthalenes; Nitric Oxide; Nitric Oxide Synthase Type III; Protein Kinase C; Saphenous Vein; Sulfonamides | 2007 |